XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis
Ting-Ting Xu, Ming-Ci Cai, Shu Cheng, Yao-Hui Huang, Qian-Qian Zhang, Peng-Peng Xu, Li Wang, Yu-Ran Qiu, Wei-Li Zhao · 2025
Read XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis by Ting-Ting Xu, Ming-Ci Cai, Shu Cheng, Yao-Hui Huang, Qian-Qian Zhang, Peng-Peng Xu, Li Wang, Yu-Ran Qiu, Wei-Li Zhao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12729132.txt.
Description
A hard-to-treat form of T-cell lymphoma carries mutations in both the TET2 and RHOA genes, and standard chemotherapy often fails these patients. Ting-Ting Xu and co-authors screen 633 anti-tumor compounds for a partner that strengthens azacitidine, a drug already used against this cancer. One partner stood out: selinexor, a drug that blocks the export protein XPO1.
Together the two drugs killed lymphoma cells and shrank tumors in fish and mouse models far better than either alone. The pair works by suppressing a growth signal chain, JAK3 and STAT3. A patient treated with the combination is also described. The authors propose the pairing as a targeted option for a mutation group with few choices.
Catalog record
| CREATOR | Ting-Ting Xu, Ming-Ci Cai, Shu Cheng, Yao-Hui Huang, Qian-Qian Zhang, Peng-Peng Xu, Li Wang, Yu-Ran Qiu, Wei-Li Zhao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |